Back to School: How biopharma can reboot drug development. Access exclusive analysis here

DG031: Phase IIa completed enrollment

DCGN completed enrollment of 200 patients in a Phase

Read the full 90 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE